AstraZeneca Shares Rise, Q2 Revenue Boosted By Oncology and Biopharmaceuticals Growth

AstraZeneca (LON: AZN) shares rose on Tuesday after the pharmaceutical giant posted better-than-expected second-quarter results, driven by strong growth in Oncology and BioPharmaceuticals.

Total revenue for the second quarter rose 12% year-on-year to $14.46 billion, ahead of the $14.15 billion consensus forecast provided by the company.

Core earnings per share came in at $2.17, also beating the consensus estimate of $2.16. 

For the first half of 2025, total revenue increased 11% at constant exchange rates to $28.05 billion, with core EPS up 17% to $4.66.

Growth was broad-based, with product sales rising 10% in Q2 and alliance revenue increasing by 35%. 

AstraZeneca reported strong performances across all major geographic regions, along with 12 positive Phase III readouts and 19 regulatory approvals during the period.

AstraZeneca shares are up around 1% so far on Tuesday. This year, the stock has gained just over 5%. However, in the last 12 months, it has declined 10.7%. 

“Our strong momentum in revenue growth continued through the first half of the year,” said CEO Pascal Soriot. “Delivery from our broad and diverse pipeline has been excellent.”

The company maintained its full-year guidance, expecting total revenue to rise by a high single-digit percentage and core EPS to increase by a low double-digit percentage.

AstraZeneca also highlighted its planned $50 billion investment in U.S. manufacturing and R&D by 2030, including its largest-ever facility in Virginia. 

The plant is expected to support the production of the company’s metabolic and weight management treatments.